Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses
- PMID: 38739921
- PMCID: PMC12768424
- DOI: 10.7326/M23-2781
Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses
Abstract
Background: Whether circulating sex hormones modulate mortality and cardiovascular disease (CVD) risk in aging men is controversial.
Purpose: To clarify associations of sex hormones with these outcomes.
Data sources: Systematic literature review to July 2019, with bridge searches to March 2024.
Study selection: Prospective cohort studies of community-dwelling men with sex steroids measured using mass spectrometry and at least 5 years of follow-up.
Data extraction: Independent variables were testosterone, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol concentrations. Primary outcomes were all-cause mortality, CVD death, and incident CVD events. Covariates included age, body mass index, marital status, alcohol consumption, smoking, physical activity, hypertension, diabetes, creatinine concentration, ratio of total to high-density lipoprotein cholesterol, and lipid medication use.
Data synthesis: Nine studies provided individual participant data (IPD) (255 830 participant-years). Eleven studies provided summary estimates (n = 24 109). Two-stage random-effects IPD meta-analyses found that men with baseline testosterone concentrations below 7.4 nmol/L (<213 ng/dL), LH concentrations above 10 IU/L, or estradiol concentrations below 5.1 pmol/L had higher all-cause mortality, and those with testosterone concentrations below 5.3 nmol/L (<153 ng/dL) had higher CVD mortality risk. Lower SHBG concentration was associated with lower all-cause mortality (median for quintile 1 [Q1] vs. Q5, 20.6 vs. 68.3 nmol/L; adjusted hazard ratio [HR], 0.85 [95% CI, 0.77 to 0.95]) and lower CVD mortality (adjusted HR, 0.81 [CI, 0.65 to 1.00]). Men with lower baseline DHT concentrations had higher risk for all-cause mortality (median for Q1 vs. Q5, 0.69 vs. 2.45 nmol/L; adjusted HR, 1.19 [CI, 1.08 to 1.30]) and CVD mortality (adjusted HR, 1.29 [CI, 1.03 to 1.61]), and risk also increased with DHT concentrations above 2.45 nmol/L. Men with DHT concentrations below 0.59 nmol/L had increased risk for incident CVD events.
Limitations: Observational study design, heterogeneity among studies, and imputation of missing data.
Conclusion: Men with low testosterone, high LH, or very low estradiol concentrations had increased all-cause mortality. SHBG concentration was positively associated and DHT concentration was nonlinearly associated with all-cause and CVD mortality.
Primary funding source: Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668).
Conflict of interest statement
Figures
References
-
- Yeap BB, Alfonso H, Chubb SA, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012; 97: 4030–4039. - PubMed
-
- Shi Z, Araujo AB, Martin S, et al. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab 2013; 98: 3289–3297. - PubMed
-
- Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445–455. - PubMed
-
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone replacement therapy. N Engl J Med 2023; 389: 107–117. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 HC085080/HL/NHLBI NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- N01 HC085082/HL/NHLBI NIH HHS/United States
- U01 HL130114/HL/NHLBI NIH HHS/United States
- U01 AG042145/AG/NIA NIH HHS/United States
- U01 AG042168/AG/NIA NIH HHS/United States
- 75N92021D00006/HL/NHLBI NIH HHS/United States
- 75N92019D00031/HL/NHLBI NIH HHS/United States
- U01 AG027810/AG/NIA NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- R01 HL134320/HL/NHLBI NIH HHS/United States
- U01 AG042143/AG/NIA NIH HHS/United States
- U01 AR066160/AR/NIAMS NIH HHS/United States
- HHSN268200800007C/HL/NHLBI NIH HHS/United States
- UL1 TR002369/TR/NCATS NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- N01 HC085083/HL/NHLBI NIH HHS/United States
- R01 AG066671/AG/NIA NIH HHS/United States
- U01 AG042124/AG/NIA NIH HHS/United States
- HHSN268201200036C/HL/NHLBI NIH HHS/United States
- HHSN268201800001C/HL/NHLBI NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- U01 AG042140/AG/NIA NIH HHS/United States
- N01 HC085081/HL/NHLBI NIH HHS/United States
- U01 AG042139/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous